The frequent upregulation of CDK6 (237, 235) in hematopoietic tumors (243, 244) and the fact that alterations of INK4 proteins are commonly found in hematopoietic tumors demands for the understanding of any CDK6-INK4 correlation in leukemia/lymphoma to exploit CDK4/6 inhibitors in hematopoietic malignancies. This evidence concerns the gene CDK6 and hematopoietic and lymphoid cell neoplasm.